References
- Leopold CPharmaceutical policy analysis—a European perspective on pricing and reimbursement in challenging times2014UtrechtUtrecht University
- Fischer KEA systematic review of coverage decision-making on health technologies—evidence from the real worldHealth Policy20121072–3218230 10.1016/j.healthpol.2012.07.005 22867939
- Panteli D, Eckhardt H, Nolting A, Busse R, Kulig MFrom market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countriesHealth Res Policy Syst201513118 10.1186/s12961-015-0028-5
- Allen N, Liberti L, Walker SR, Salek SA comparison of reimbursement recommendations by European HTA agencies: is there opportunity for further alignment?Front Pharmacol20178384 10.3389/fphar.2017.00384 28713265 5491965
- Barnieh L, Manns B, Harris A, Blom M, Donaldson C, Klarenbach S, et al.A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countriesValue Health201417198108 10.1016/j.jval.2013.10.008 24438723
- Neumann PJ, Bliss SK, Chambers JDTherapies for advanced cancers pose a special challenge for health technology assessment organizations in many countriesHealth Aff2012314700708 10.1377/hlthaff.2011.1309
- Alexander GC, O'Connor AB, Stafford RSEnhancing prescription drug innovation and adoptionAnn Intern Med201115412833837 10.7326/0003-4819-154-12-201106210-00012 21690598 4049188
- Wang S, Gum D, Merlin TComparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?Value Health2018218938943 10.1016/j.jval.2018.01.017 30098671
- Dakin H, Devlin N, Feng Y, Rice N, O'Neill P, Parkin DThe influence of cost-effectiveness and other factors on nice decisionsHealth Econ2015241012561271 10.1002/hec.3086 25251336
- Buxton MJEconomic evaluation and decision making in the UKPharmacoeconomics2006241111331142 10.2165/00019053-200624110-00009 17067197
- Ewbank L, Omojomolo D, Sullivan K, McKenna H. The rising cost of medicines to the NHS. The Kings Fund. 2018:2018-04.
- NHS. Appraisal and funding of cancer drugs from July 2016 (including the new cancer drugs fund); 2016. https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf.
- NICE. Budget impact test; 2017. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/budget-impact-test.
- Parkinson BT. Pharmaceutical policy in Australia: developing methods to manage uncertainty in health technology assessment; 2015.
- Levy AR, Mitton C, Johnston KM, Harrigan B, Briggs AHInternational comparison of comparative effectiveness research in five jurisdictionsPharmacoeconomics20102810813830 10.2165/11536150-000000000-00000 20831289
- George B, Harris A, Mitchell ACost-effectiveness analysis and the consistency of decision makingPharmacoeconomics2001191111031109 1:STN:280:DC%2BD3Mnpt1yitQ%3D%3D 10.2165/00019053-200119110-00004 11735677
- PBS. Trastuzumab, powder for I.V. infusion, 150 mg, Herceptin®, November 2008. https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2008-11/pbac-psd-trastuzumab-nov08.
- Chim L, Kelly PJ, Salkeld G, Stockler MRAre cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?Pharmacoeconomics2010286463475 10.2165/11533000-000000000-00000 20465315
- PBAC. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee; 2015. https://pbac.pbs.gov.au/content/information/archived-versions/pbac-guidelines-v4-5.pdf.
- Chinitz D, Israeli AHealth reform and rationing in IsraelHealth Aff1997165205210 1:STN:280:DyaK2svmtVaktQ%3D%3D 10.1377/hlthaff.16.5.205
- Parsons A, Johnstone APostcode prescribing and the Human Rights Act 1998J R Soc Med2001944159160 1:STN:280:DC%2BD3M3kvFSnsw%3D%3D 10.1177/014107680109400401 11317614 1281383
- Sax PThe shaping of pharmaceutical governance: the Israeli caseIsrael J Health Policy Res20143116 10.1186/2045-4015-3-16
- Shalev C, Chinitz DJoe public v. the general public: the role of the courts in Israeli health care policyJ Law Med Ethics2005334650659 10.1111/j.1748-720X.2005.tb00533.x 16686236
- Wolf I, Waissengrin B, Zer A, Bernstein-Molho R, Rouvinov K, Cohen JE, et al.Implementation of the ESMO-magnitude of clinical benefit scale: real world example from the 2022 Israeli National Reimbursement ProcessESMO Open.202271 1:STN:280:DC%2BB2M7ntlGjtA%3D%3D 10.1016/j.esmoop.2021.100379 35121523 8818899
- Clarfield AM, Manor O, Nun GB, Shvarts S, Azzam ZS, Afek A, et al.Health and health care in Israel: an introductionLancet20173891008825032513 10.1016/S0140-6736(17)30636-0 28495109
- Shani S, Siebzehner MI, Luxenburg O, Shemer JSetting priorities for the adoption of health technologies on a national level—the Israeli experienceHealth Policy2000543169185 1:STN:280:DC%2BD38%2Fgs1WqtA%3D%3D 10.1016/S0168-8510(00)00109-3 11154787
- Fischer KE, Heisser T, Stargardt THealth benefit assessment of pharmaceuticals: an international comparison of decisions from Germany, England, Scotland and AustraliaHealth Policy20161201011151122 10.1016/j.healthpol.2016.08.001 27628196
- Chapman S, Paris V, Lopert R. Challenges in access to oncology medicines: policies and practices across the OECD and the EU. 2020.
- FDA. FDA approves pembrolizumab for patients with non-small cell lung cancer; 2015. https://www.cancer.gov/news-events/cancer-currents-blog/2015/pembrolizumab-nsclc#:~:text=On%20October%202%2C%20the%20Food,progressed%20after%20platinum%2Dbased%20chemotherapy.
- NICE. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy TA428; 2017. https://www.nice.org.uk/guidance/ta428/chapter/1-Recommendations.
- PBAC. Pembrolizumab (NSCLC): powder for injection 50mg; Keytruda; 2016. https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2016-11/files/pembrolizumab-nsclc-psd-november-2016.pdf.
- FDA. Pembrolizumab (KEYTRUDA) checkpoint inhibitor; 2016. https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda-checkpoint-inhibitor.
- NICE. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer TA447; 2017. https://www.nice.org.uk/guidance/ta447.
- NICE. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer TA531; 2018 [9th December 2021]. https://www.nice.org.uk/guidance/ta531/chapter/1-Recommendation.
- PBAC. Pembrolizumab (NSCLC): powder for injection 50 mg; solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda; 2018. https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2018-07/files/pembrolizumab-nsclc-psd-july-2018.pdf.
- FDA. FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC; 2018. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic.
- FDA. FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC; 2018. https://www.fda.gov/drugs/fda-approves-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic-squamous-nsclc.
- NICE. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer TA557; 2019. https://www.nice.org.uk/guidance/ta557.
- NICE. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer TA683; 2021. https://www.nice.org.uk/guidance/ta683/chapter/1-Recommendations.
- NICE. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer TA600; 2019. https://www.nice.org.uk/guidance/ta600.
- PBAC. Pembrolizumab solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda. 2019. https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-07/files/pembrolizumab-nsclc-psd-july-2019.pdf.
- Lublóy ÁFactors affecting the uptake of new medicines: a systematic literature reviewBMC Health Serv Res2014141469 10.1186/1472-6963-14-469 25331607 4283087
- Medlinskiene K, Tomlinson J, Marques I, Richardson S, Stirling K, Petty DBarriers and facilitators to the uptake of new medicines into clinical practice: a systematic reviewBMC Health Serv Res20212111198 10.1186/s12913-021-07196-4 34740338 8570007
- Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJUsing effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and CanadaJAMA20093021314371443 1:CAS:528:DC%2BD1MXht1CksrbN 10.1001/jama.2009.1409 19809025
- Pujolras LM, Cairns JWhy do some countries approve a cancer drug and others don’t?J Cancer Policy201542125 10.1016/j.jcpo.2015.05.004
- Pharmaceutical industry competitiveness task force; 2001. https://www.rieti.go.jp/jp/events/bbl/data/pictf.pdf.
- Sciences OfL. Life sciences competitiveness indicators. 2019. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/811347/life-sciences-competitiveness-data-2019.pdf.
- Chauhan D, Mason AFactors affecting the uptake of new medicines in secondary care—a literature reviewJ Clin Pharm Ther2008334339348 1:STN:280:DC%2BD1cvktV2gsA%3D%3D 10.1111/j.1365-2710.2008.00925.x 18613851
- Fund TK. Access to new medicines in the English NHS; 2020. https://www.kingsfund.org.uk/publications/access-new-medicines-english-nhs.
- Guttman N, Shalev C, Kaplan G, Abulafia A, Bin-Nun G, Goffer R, et al.What should be given a priority–costly medications for relatively few people or inexpensive ones for many? The Health Parliament public consultation initiative in IsraelHealth Expect2008112177188 10.1111/j.1369-7625.2007.00485.x 18429997 5060441
- Shaw B. Deferring PBAC decisions: industry view. An independent review. 2012:3.
- News IH. Cancer patients fear ahead of drug basket discussions: “who will make our voices heard in committee?” 2021. https://www.israelhayom.co.il/health/article/4850070.
- Beyar R, Zeevi B, Rechavi GIsrael: a start-up life science nationLancet20173891008825632569 10.1016/S0140-6736(17)30704-3 28495116
- Stafinski T, Menon D, Marshall D, Caulfield TSocietal values in the allocation of healthcare resourcesPatient Patient-Cent Outcomes Res201144207225 10.2165/11588880-000000000-00000
- Jotkowitz AB, Agbaria R, Glick SMMedical ethics in Israel—bridging religious and secular valuesLancet20173891008825842586 10.1016/S0140-6736(17)30700-6 28495111
- NICE. The principles that guide the development of NICE guidance and standards. https://www.nice.org.uk/about/who-we-are/our-principles.
- Mobinizadeh M, Raeissi P, Nasiripour AA, Olyaeemanesh A, Tabibi SJThe health systems’ priority setting criteria for selecting health technologies: a systematic review of the current evidenceMed J Islam Repub Iran201630329 27390699 4898853
- Golan O, Hansen PWhich health technologies should be funded? A prioritization framework based explicitly on value for moneyIsrael J Health Policy Res201211114 10.1186/2045-4015-1-44
- Nicod E, Kanavos PCommonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisionsHealth Policy20121082–3167177 10.1016/j.healthpol.2012.09.012 23088802
- Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, et al.Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictionsCEOR2013569
- Lim CS, Lee Y-G, Koh Y, Heo DSInternational comparison of the factors influencing reimbursement of targeted anti-cancer drugsBMC Health Serv Res2014141110 10.1186/s12913-014-0595-0
- Salas-Vega S, Bertling A, Mossialos EA comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UKHealth Policy20161201011041114 10.1016/j.healthpol.2016.08.006 27665497
- Allen N, Walker SR, Liberti L, Salek SHealth technology assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England, and ScotlandValue Health2017203320328 10.1016/j.jval.2016.10.014 28292476
- Nicod EWhy do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countriesEur J Health Econ2017186715730 10.1007/s10198-016-0823-0 27538758
- Rosen B, Waitzberg R, Israeli AIsrael’s rapid rollout of vaccinations for COVID-19Israel J Health Policy Res20211016 10.1186/s13584-021-00440-6